Standard Biotools (LAB) Operating Income (2010 - 2026)

Standard Biotools (LAB) has 17 years of Operating Income data on file, last reported at -$12.5 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$12.5 million, up 53.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$95.8 million (down 6242.72% YoY), and the FY2025 annual result was -$110.2 million, down 480.78% from the prior year.
• Operating Income advanced to -$12.5 million in Q1 2026 per LAB's latest filing, from -$24.6 million in the prior quarter.
• Over five years, Operating Income peaked at $82.4 million in Q4 2024 and troughed at -$60.2 million in Q1 2024.
• A 5-year average of -$17.0 million and a median of -$25.7 million in 2025 frame the typical range for Operating Income.
• The sharpest annual moves came in 2023 and 2024: Operating Income jumped 287.72% in 2023, then slumped 262.7% in 2024.
• A 5-year view of Operating Income shows it stood at -$21.1 million in 2022, then jumped by 287.72% to $39.6 million in 2023, then jumped by 107.97% to $82.4 million in 2024, then tumbled by 129.9% to -$24.6 million in 2025, then surged by 49.29% to -$12.5 million in 2026.
• Business Quant data shows LAB's Operating Income at -$12.5 million in Q1 2026, -$24.6 million in Q4 2025, and -$32.9 million in Q3 2025.